Wristband that provides relief for upper limb tremor is approved; FDA warns of clinically significant weight loss in younger kids taking ADHD meds; REMS removed for CAR T-cell immunotherapies; ...

“While the phase 3 results of GCAptAIN did not replicate the positive outcomes observed in the phase 2 trial, we remain committed to continuing to drive scientific progress and deepening the ...

The Food and Drug Administration (FDA) has granted accelerated approval to Lynozyfic™ (linvoseltamab-gcpt) for the treatment of adult patients with ...

HealthDay News — Attention-deficit/hyperactivity disorder (ADHD) medications remain associated with a reduced risk for various real-world outcomes, but the magnitude of these associations decreases ...

The approval of sunvozertinib, an oral irreversible EGFR inhibitor, was supported by data from the WU-KONG1B trial (ClinicalTrials.gov Identifier: NCT03974022 ). The primary efficacy population ...

The wearable, transcutaneous neurostimulation device delivers personalized therapy using a proprietary AI algorithm.

An mRNA-based flu vaccine has the potential advantage to more precisely match circulating strains, support rapid response in a future influenza pandemic, and pave the way for COVID-19 combination ...

The decision came Tuesday from US District Judge Melissa DuBose in response to a lawsuit filed by attorneys general from 19 states and the District of Columbia, the Associated Press reported. DuBose ...

The Children’s Health Defense sued Meta Platforms, the parent company of Facebook and Instagram. It claimed the company removed their content in violation of free speech rights, NBC News reported.

We spoke with Dr Kellan Baker of the Whitman-Walker institute to shed some light on the many changes taking place to various aspects of medical care for LGBTQ+ individuals.

Gammagard Liquid ERC is a ready-to-use formulation with low IgA content designed to ease administration burden by removing the need to reconstitute.

Previously, due to the risk of cytokine release syndrome and neurological toxicities, many CAR T-cell therapies included a REMS requirement.